Just In
- 48 min ago These Common Habits Can Be Insidious, Can Hurt Any Partner And Ruin Any Relationship
- 3 hrs ago What Is Porcelain Doll Makeup Trend? 6 Tips To Achieve The Doll-like Glamour
- 5 hrs ago These Zodiac Signs Are Extremely Stubborn And Struggle When It Comes To Apologizing
- 7 hrs ago Daily Horoscope, 18 April 2024: Libra Will See Financial Success, Relationship With Spouse Will Improve
Don't Miss
- Finance Green Deposit Showdown: SBI Vs Bank Of Baroda Interest Rates
- Movies Varshangalkku Shesham Box Office Collection: Vineeth Sreenivasan's Film Shines; Makes Over Rs 50 Crore
- Education IIT Madras Introduces International master's course on Water Security and Global Change
- Technology Realme C65 Reportedly Launching Soon in India - Check Expected Price & Specs
- News ED Attaches Actress Shilpa Shetty's Juhu Flat, Raj Kundra's Properties In Money Laundering Case
- Sports Why is Dhanashree Verma not attending IPL 2024 matches of husband Yuzvendra Chahal?
- Automobiles Kerala Spearheads Revival of Iconic Double-Decker Trains in India
- Travel From Coconut Breaking on Head to Men Dressing as Women: 12 Unique Indian Rituals Explored
New anti-diabetic agent from Reddy's Labs beibng tested
Hyderabad, Dec 26 (UNI) An anti-diabetic agent that works through new pathways, discovered by Dr Reddy's Laboratories and taken up for development by Perlecan Pharma, is undergoing Phase I clinical trials in the Netherlands.
The agent, DRL 16536, works by activating the biological pathways responsible for beneficial effects of exercise. Targeting the exercise pathway using the drug has lowered glucose and lipid values significantly in pre-clinical trials. It has additional benefit of weight loss.
Current treatment options for Type 2 diabetes work through other mechanisms and might not provide the overall beneficial clinical effects needed, which encompass glycemic control, lipid control and body weight loss, a statement from the two organisations here said.
DRL 16536 has been extensively studied in pre-clinical pharmacokinetic and toxicology experiment. It has demonstrated good oral bioavailability in animal models with adequate safety established in toxicology studies, it said.
The
Phase
I
clinical
trials
would
test
the
safety
and
tolerability
of
DRL-16536
in
healthy
volunteers.
Chairman,
Perlecan
Pharma
and
Founder-Chairman,
Dr
Reddy's
Laboratories,
Dr
K
Anji
Reddy
said
in
the
statement
that
'DRL
16536
is
the
fourth
asset
from
Perlecan
and
the
third
''first-in-class''
compound
from
Dr
Reddy's
discovery
research,
to
go
into
clinical
development.
With
the
experience
gained
in
modulation
of
this
target,
we
at
Dr
Reddy's
are
confident
of
discovering
drugs
for
prevention
and
treatment
of
metabolic
syndromes.'